NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market...
SKIA HEAD: AR Surgical Guidance Receives FDA 510(k) Clearance, Eyes U.S. Expansion with Structure Partnership
SEOUL, South Korea, May 29, 2026 /PRNewswire/ -- South Korea-based medtech innovator SKIA has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its augmented reality (AR) surgical guidance system, SKIA HEAD....
Creality Falcon T1 5-in-1 Laser Engraver Now Available -- Top Creators Put It to the Test
The world's first five-in-one laser workstation, validated by creators worldwide. Presale Offer Now from $2249, 10% OFF for a Limited Time. Limited stocks in the US and EU. NEW YORK, May 29, 2026 /PRNewswire/ -- Creality Falcon has officially...
INPARADISE Partners with Michelin Guide-Recommended Chef Daniel Sanz Martin for an Exclusive Culinary Collaboration
【Taste the World, INPARADISE】Chapter Two: Spain Reinterpreting the Flavors of Spain Through a Contemporary Culinary Lens TAIPEI, May 29, 2026 /PRNewswire/ -- Following the success of its inaugural Italian chapter, Taipei's acclaimed sky-high buffet...
Azazie Expands Texas Pop-Up Tour Across Houston, Dallas, Austin & San Antonio
The leading bridal and occasionwear brand continues its rapid Texas expansion with immersive shopping experiences throughout Spring, Summer, and Fall 2026 LOS ANGELES, Calif., May 29, 2026 /PRNewswire/ -- Azazie, the leading direct-to-consumer...
Holmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral Health
Expansion anchored by two top neurological health systems, structured AD biomarker data, and validated outcomes measures across neurological disease areas. Whole-population ingestion shifts NeuroBlu from patient counts to research-grade signal. NEW...
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
ZEGFROVY ® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins WU-KONG28 is the first global randomized phase 3 study with positive results for an oral,...
Yoma Strategic Posts Record Revenue and 76% Profit Surge, Validating Turnaround Strategy
Operating cash flow more than doubles; broad-based growth across key business units. SINGAPORE, May 29, 2026 /PRNewswire/ -- Yoma Strategic Holdings Ltd. ("Yoma Strategic" or "the Group") today announced its full-year financial results for the...